TSOI files new Patent on Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof

May 22, 2017 09:00 ET

Company Developing Proprietary Products that Help Immune System Fight Cancer

OCEANSIDE, CA–(Marketwired – May 22, 2017) – Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent covering a repurposing of the FDA cleared drug Mifepristone for use in expansion of T and NK cells in cancer patients undergoing immunotherapy.

The patent describes methods useful for improving a treatment outcome and/or an alteration of immunity in a condition that benefits from immune stimulation. In particular, the invention teaches administration of sufficient doses of Mifepristone or a derivative, alone, or in combination with an immunotherapeutic such as an antibody, a vaccine, a cytokine, or a medicament whose therapeutic activity is associated with immune modulation.

LymphoBoost is a proprietary formulation of Mifepristone, a drug approved for another indication, which we have shown to be capable of stimulating lymphocytes, particularly NK cells and T cells, both critical in maintaining anti-tumor immunity.

“Current cancer therapies are often associated with various degrees of toxicity. One of the Company’s core principles is to develop approaches that are unlikely to cause toxicity by focusing on naturally occurring products or repurposing of drugs that are already demonstrated to be safe,” said Timothy Dixon, President and CEO of Therapeutic Solutions International. “Mifepristone has been used in the USA since the year 2000 for its anti-progesterone properties and its safety and pharmacology are well characterized.”

“The immune system does not work in isolation of other physiological systems of the body,” said Dr. Thomas Ichim, Director of Therapeutic Solutions International. “Various types of tumors have been shown to generate Progesterone Induced Blocking Factor1,2,3 which suppresses the immune cells whose role it is to kill the tumor4,5. By blocking progesterone activity with Mifepristone, our data suggests the possibility of overcoming some aspects of cancer induced immune suppression.”

1 Gutiérrez-Rodríguez et al. Proliferative and Invasive Effects of Progesterone-Induced Blocking Factor in Human Glioblastoma Cells. Biomed Res Int.2017;2017:1295087. https://www.ncbi.nlm.nih.gov/pubmed/28168193
2 Marquina-Sánchez et al. The interplay between intracellular progesterone receptor and PKC plays a key role in migration and invasion of human glioblastoma cells. J Steroid Biochem Mol Biol. 2016 Oct 4. pii: S0960-0760(16)30261-8. https://www.ncbi.nlm.nih.gov/pubmed/27717886
3 Kyurkchiev et al. Cells isolated from human glioblastoma multiforme express progesterone-induced blocking factor (PIBF). Cell Mol Neurobiol. 2014 May;34(4):479-89. https://www.ncbi.nlm.nih.gov/pubmed/24474429
4 Par et al. Progesterone regulates IL12 expression in pregnancy lymphocytes by inhibiting phospholipase A2.
Am J Reprod Immunol. 2003 Jan;49(1):1-5. https://www.ncbi.nlm.nih.gov/pubmed/12733588
5 Faust et al. Progesterone-induced blocking factor inhibits degranulation of natural killer cells.
Am J Reprod Immunol. 1999 Aug;42(2):71-5. https://www.ncbi.nlm.nih.gov/pubmed/10476687

About Therapeutic Solutions International, Inc.
The Company’s corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.

These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.